Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Akebia Therapeutics (AKBA) Gains from Sales and Divestitures (2016 - 2019)

Historic Gains from Sales and Divestitures for Akebia Therapeutics (AKBA) over the last 4 years, with Q4 2019 value amounting to $323136.0.

  • Akebia Therapeutics' Gains from Sales and Divestitures fell 6051.59% to $323136.0 in Q4 2019 from the same period last year, while for Dec 2019 it was $323136.0, marking a year-over-year decrease of 6051.59%. This contributed to the annual value of $323136.0 for FY2019, which is 6051.59% down from last year.
  • According to the latest figures from Q4 2019, Akebia Therapeutics' Gains from Sales and Divestitures is $323136.0, which was down 6051.59% from $818395.0 recorded in Q4 2018.
  • Akebia Therapeutics' 5-year Gains from Sales and Divestitures high stood at $818395.0 for Q4 2018, and its period low was $90566.0 during Q4 2017.
  • For the 4-year period, Akebia Therapeutics' Gains from Sales and Divestitures averaged around $335196.2, with its median value being $215912.0 (2016).
  • In the last 5 years, Akebia Therapeutics' Gains from Sales and Divestitures skyrocketed by 80364.49% in 2018 and then crashed by 6051.59% in 2019.
  • Over the past 4 years, Akebia Therapeutics' Gains from Sales and Divestitures (Quarter) stood at $108688.0 in 2016, then dropped by 16.67% to $90566.0 in 2017, then skyrocketed by 803.64% to $818395.0 in 2018, then crashed by 60.52% to $323136.0 in 2019.
  • Its Gains from Sales and Divestitures was $323136.0 in Q4 2019, compared to $818395.0 in Q4 2018 and $90566.0 in Q4 2017.